Although ICIs have had a major impact on the therapy of many tumor types and subsequent patients’ lives, the observation of primary and acquired resistance to anti-PD1/PD-L1 and anti-CTLA4 agents leave much room for improvement. This evidence concerns the gene CD274 and neoplasm.